Project Grant HT9425261E153
Award Date 6/15/26
Completion Date 6/14/28
Dollars Obligated $832K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Greece
Similar Awards
- The Defense Health Agency (DHA) awarded The Washington University a $840,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2028. The award funds research investigating hyperphosphorylation of tau serine 262 as a novel biomarker and therapy target in amyotrophic lateral sclerosis (ALS). The research will be conducted at the university's Office of Sponsored Research Services Division in University City, Missouri, and...
- The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
- The Defense Health Agency awarded a $659,922 Project Grant to Macquarie University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds a gene therapy research project aimed at developing a treatment for delaying the onset of Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The research will be conducted at Macquarie University over a 2-year period from September 2025 to September 2027. This project grant is part of...
- Federal Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine received a $999,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on June 1, 2026, with a completion date of May 31, 2029. This award supports the development of a Schwann cell-derived extracellular vesicle platform designed to advance biomarker discovery for amyotrophic lateral sclerosis (ALS) in...
- New York University School of Medicine received a $1.0 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded June 1, 2026, with completion targeted for May 31, 2029. The award funds research to develop and validate diffusion magnetic resonance imaging (MRI) biomarkers for detecting axonal degeneration in amyotrophic lateral sclerosis (ALS). This research initiative supports the DHA's mission to advance...
- Federal Project Grant Award Summary Arizona State University received a $962,713 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on June 15, 2025, with a completion date of June 14, 2028. The award supports research focused on developing robust subtype markers for amyotrophic lateral sclerosis (ALS) patient stratification. This initiative aligns with the DHA's mission to advance biomedical research that transforms...
- Federal Grant Award Summary Case Western Reserve University's Office of Research Administration received a $839,998 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded July 1, 2026, with a performance period through June 30, 2028. The award supports research into pharmacological stabilization of the calpain-2 complex as a novel translational therapeutic approach for amyotrophic lateral sclerosis (ALS). This...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $939,325 to the Weizmann Institute of Science on November 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to support the GLOBALS (Global Omic Biomarker Research for ALS) initiative. This three-year project, extending through October 31, 2028, funds advanced biomedical research focused on discovering and developing omic biomarkers for amyotrophic lateral sclerosis (ALS). The research...
- Federal Grant Award Summary Emory University received a $840,000 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period April 1, 2026 through March 31, 2028. The award supports research focused on "Repurposing Approved Drugs as First-in-Class Disruptors of the P38/MK2 Complex to Suppress Neuroinflammation in ALS" (amyotrophic lateral sclerosis). The research will be conducted at Emory University's...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Monash University a $839,940 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2028. The award supports research on multisensory stimulation and Piezo1 as therapeutic strategies targeting glymphatic and meningeal lymphatic clearance in amyotrophic lateral sclerosis (ALS). This hypothesis-driven research initiative seeks to develop innovative medical...